Novel Targeting Moiety and Payload Conjugates Summit Europe

Join us at the inaugural Novel Targeting Moiety and Payload Conjugate Summit Europe, the premier event for Europe's burgeoning novel drug conjugate market. With more companies than ever before utilising novel targeting moieties and novel payloads to widen the therapeutic index of their conjugate, this meeting will act as your gateway to explore how design approaches range from peptide-drug conjugates, bispecific-drug conjugates, antibody-oligonucleotide conjugates, radio-conjugates, and fragment drug conjugates.

Learn how alterations in the targeting moiety and payload can enhance target specificity and reduce off-target toxicity, improve tumour penetration in solid tumours, prevail over oligonucleotide delivery challenges, and improve PK properties to maximise efficacy and reduce toxicity.

Offering a platform for innovative biotechs to showcase how their technologies can address the challenges limiting the application of ADCs, this meeting will bring together a unique audience of C-level executives from European biotechs, Director through to Scientists from large pharma working on and exploring how to expand the conjugate design toolkit.

As the only event in Europe spotlighting novel conjugate approaches in a room of highly invested individuals; this event is novel by name and nature!

Don't miss out on shaping the future of targeted therapeutics in Europe!

Date and Time: Tuesday, 24 September 2024 at 08:00 to Thursday, 26 September 2024 at 17:00